newsfilter
← Latest News
GlobeNewswire·

Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures

TORONTO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of